BPC157 as Potential Agent Rescuing from Cancer Cachexia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun A. | - |
dc.contributor.author | Han, Young-Min | - |
dc.contributor.author | An, Jeong Min | - |
dc.contributor.author | Park, Yong Jin | - |
dc.contributor.author | Sikiric, Predrag | - |
dc.contributor.author | Kim, Deok Hwan | - |
dc.contributor.author | Kwon, Kwang An | - |
dc.contributor.author | Kim, Yoon Jae | - |
dc.contributor.author | Yang, Donghwa | - |
dc.contributor.author | Tchah, Hann | - |
dc.contributor.author | Hahm, Ki Baik | - |
dc.date.available | 2020-02-27T15:43:25Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5255 | - |
dc.description.abstract | Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system related-or inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions, | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BENTHAM SCIENCE PUBL LTD | - |
dc.relation.isPartOf | CURRENT PHARMACEUTICAL DESIGN | - |
dc.subject | PENTADECAPEPTIDE BPC-157 | - |
dc.subject | MODEL | - |
dc.subject | PATHOPHYSIOLOGY | - |
dc.subject | MECHANISMS | - |
dc.subject | SARCOPENIA | - |
dc.subject | THERAPY | - |
dc.subject | FISTULA | - |
dc.subject | ULCER | - |
dc.subject | RATS | - |
dc.title | BPC157 as Potential Agent Rescuing from Cancer Cachexia | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000441085700004 | - |
dc.identifier.doi | 10.2174/1381612824666180614082950 | - |
dc.identifier.bibliographicCitation | CURRENT PHARMACEUTICAL DESIGN, v.24, no.18, pp.1947 - 1956 | - |
dc.identifier.scopusid | 2-s2.0-85053607364 | - |
dc.citation.endPage | 1956 | - |
dc.citation.startPage | 1947 | - |
dc.citation.title | CURRENT PHARMACEUTICAL DESIGN | - |
dc.citation.volume | 24 | - |
dc.citation.number | 18 | - |
dc.contributor.affiliatedAuthor | Kwon, Kwang An | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.contributor.affiliatedAuthor | Yang, Donghwa | - |
dc.contributor.affiliatedAuthor | Tchah, Hann | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Cancer cachexia | - |
dc.subject.keywordAuthor | BPC157 | - |
dc.subject.keywordAuthor | muscle atrophy | - |
dc.subject.keywordAuthor | cytoprotection | - |
dc.subject.keywordAuthor | hypercatabolism | - |
dc.subject.keywordAuthor | hypoanabolism | - |
dc.subject.keywordPlus | PENTADECAPEPTIDE BPC-157 | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordPlus | PATHOPHYSIOLOGY | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | SARCOPENIA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | FISTULA | - |
dc.subject.keywordPlus | ULCER | - |
dc.subject.keywordPlus | RATS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.